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Abstract 
Several patients have been described recently who suffer from a non-rhizomelic type of chondrodysplasia punctata (CDP), but who 
show all the biochemical abnormalities characteristic of the rhizomelic form of chondrodysplasia punctata (RCDP), a peroxisomal 
disorder. We have used protease protection experiments and microinjection ofreporter-protein-encoding expression plasmids to show that 
peroxisomal thiolase fails to be imported into peroxisomes in cells from non-rhizomelic CDP patients, as has already been found in cells 
from classical RCDP patients. Furthermore, complementation analysis after somatic ell fusion indicates that the non-rhizomelic CDP 
patients are impaired in the same gene as classical RCDP patients. We conclude that defects in a single gene can give rise to both clinical 
phenotypes. 
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1. Introduction 
The rhizomelic form of chondrodysplasia punctata 
(RCDP) is an autosomal recessive disease characterised 
clinically by symmetrical shortening of the proximal ex- 
tremities, congenital contractures, typical craniofacial dys- 
morphism with characteristic ocular involvement, severe 
mental and growth retardation and typical radiological 
abnormalities [1,2]. RCDP was assigned to the peroxiso- 
mal disease category after finding an impaired plasmalo- 
gen (ether phospholipid) synthesis [3]. The biochemical 
abnormalities in RCDP are now known to include (i) a 
(partial) deficiency of dihydroxyacetonephosphate acyl-
transferase; (ii) a deficiency of alkyldihydroxyacetone 
phosphate synthase; (iii) an elevation of phytanic acid due 
to the deficient a-oxidation of phytanic acid and (iv) the 
presence of peroxisomal thiolase in precursor form [2-6]. 
Abbreviations: RCDP, rhizomelic form of chondrodysplasia punctata; 
CDP, chondrodysplasia punctata; CAT, chloramphenicol acetyltransferase 
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These deficiencies are likely to be the indirect result of a 
defect in a single gene, the protein product of which may 
be involved in the import of these enzymes into peroxi- 
somes. 
Although the above-mentioned subset of peroxisomal 
functions is deficient in RCDP, peroxisomes in RCDP 
fibroblasts have been shown to be morphologically normal 
and capable of importing catalase [7] and peroxisomal 
proteins containing the (C-terminal) peroxisome targeting 
signal type 1 (PTS 1) [8]. However, proteins containing the 
type 2 peroxisome targeting signal (PTS2) (present in the 
presequence of peroxisomal thiolase) are not imported into 
peroxisomes in RCDP cells [8]. 
Several patients have been described recently who show 
chondrodysplasia punctata without he rhizomelic dwarfism 
(non-rhizomelic CDP), but biochemically show all the 
peroxisomal deficiencies characteristic of RCDP [9-12]. It 
was therefore of interest o examine the genetic relation- 
ship between the non-rhizomelic CDP patients and the 
classical RCDP patients which we have earlier found to 
fall into a single large complementation group [13]. We 
have done this using complementation a alysis following 
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somatic cell fusion. In this paper, we show that the four 
non-rhizomelic CDP patients all belong to the same com- 
plementation group as the classical RCDP patient. This 
complementation group contains, in addition to the four 
non-rhizomelic CDP patients described in this paper, fi- 
broblasts from nine classical RCDP patients [13]. 
Fig. 1. Subcellular localisation of the reporter proteins luciferase (A,B) and prethiolase-CAT (C,D) in control (A,C) and CDP1 (B,D) cells. Subcellular 
localisation ofendogenous thiolase in control (E) and CDP1 cells (F). 
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2. Materials and methods 2,3. Cell fusion and assessment of  complementation 
2. I. Cell culture 
Primary human skin fibroblasts were cultured in a 1:1 
mixture of Dulbecco's modified Eagle's Medium and 
Ham's F10 (Gibco, Glasgow, UK) supplemented with 10% 
foetal calf serum (Gibco) under 5% CO 2. The fibroblast 
lines used in the analysis were from a control subject 
(85AD5035F), from an RCDP patient (cell line MCHE 
85AD [13], from a Zellweger Syndrome patient 
((GOM85AD) belonging to complementation group III 
according to the Amsterdam nomenclature [15] and from 
three non-rhizomelic CDP patients (CDP1-4) described in 
the literature [9-12] and one unpublished patient (CDP4) 
(Barth). 
2.2. Microinjection 
24 h before microinjection the cells were plated onto 
microinjection grids. The needles were made using a PB-7 
micropipette puller (Narishage Co., Tokyo) and DNA was 
injected in reverse PBS (4 mM Na2HPO4/1 mM 
KH2PO4/140 mM KC1 (pH 7.3)) at a concentration of 
approx. 0.1 mg/ml.  18 h after microinjection, the cells 
were processed for immunofluorescence microscopy as 
previously described [7]. The expression plasmid encoding 
the PTS1 reporter protein firefly luciferase has been de- 
scribed elsewhere [8]. The expression plasmid encoding 
the PTS2 reporter protein, comprising the first 15 amino 
acids of rat thiolase fused onto bacterial chloramphenicol 
acetyltransferase (pRSV-FLT3-CAT), was a kind gift from 
S. Subramani (University of California, San Diego, CA) 
and is described by Swinkels et al. [14]. 
Fusion mediated by polyethylene glycol was carried out 
exactly as described [15]. The fusion efficiency, defined as 
the percentage of total nuclei in multinucleate cells, was 
always in the range 60-90%. The cells were processed for 
immunofluorescence using a monoclonal anti-thiolase anti- 
body 18 h after fusion. The appearance of particulate 
thiolase using indirect immunofluorescence was taken to 
indicate complementation. 
2.4. Proteinase K protection 
Cells were harvested by trypsinisation, washed twice in 
cold PBS and resuspended to a protein concentration of 
approx. 1 mg/ml  in isotonic sucrose buffer (250 mM 
sucrose, 20 mM 3-(4-morpholino)propane sulfonic acid 
(MOPS)) (pH 7.4) containing 125 /zg/ml digitonin. The 
cells were then incubated for 5 min at 37°C in digitonin 
permeabilisation buffer. This concentration of digitonin 
causes rupture of the plasma membrane, whereas the per- 
oxisomal membrane remains intact. The protease protec- 
tion assay (as described in [8] was carded out on ice using 
a Proteinase K concentration of 40 /zg/ml in the presence 
or absence of 0.5% Triton X-100. Samples were removed 
after 0.5 and 1 h, and Proteinase K action was stopped by 
addition of PMSF to 10 mM. Protection of thiolase was 
assessed by immunoblot analysis. 
2.5. Immunoblot analysis 
Samples were subjected to electrophoresis on 10% 
polyacrylamide gels according to the method of Laemmli. 
Immunoblot analyses were performed as described previ- 
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Fig. 2. Accessibility ofendogenous precursor thiolase to digestion by proteinase K in permeabilised cells from a neonatal drenoleukodystrophy (NALD) 
patient (upper panel) and CDP1 cells (lower panel). C, lysate from control cells, showing 41 kDa mature thiolase. Arrowhead shows position at which 44 
kDa precursor thiolase migrates. Band migrating above precursor thiolase isa cross-reacting band unrelated tothiolase. 
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ing sites were blocked overnight with 10% foetal calf 
serum in TBS (10 mM Tris (pH 8) /150 mM NaC1) 
containing 0.2% Tween 20. The primary (polyclonal anti- 
thiolase [16] and secondary (goat anti-rabbit-conjugated 
horseradish peroxidase (BioRad)) antibody incubations 
were performed in TBS containing 4% foetal calf serum 
and 0.1% Tween 20. The blots were washed extensively 
after each incubation in TBS containing 0.1% Tween 20. 
Fig. 3. Subcellular localisation of endogenous thiolase 18 h after fusion of fibroblast cell lines. (A) Zellweger cells X CDP1 cells; (B) CDP1 X CDP2; (C) 
CDP1 X MCHE 85AD; (D) CDP2 X MCHE 85AD; (E) CDP3 X MCHE 85AD; (F) CDP4 X MCHE 85AD. 
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Antigen-antibody complexes were visualised using the ECL 
kit from Amersham. 
3. Results 
Fibroblasts from each of the patients were tested for 
their ability to import reporter proteins for the type 1 and 2 
peroxisome targeting signals (luciferase and prethiolase- 
CAT, respectively) into their peroxisomes. A particulate 
pattern of labelling was seen in control fibroblasts after 
expression of both luciferase (Fig. 1A) and prethiolase- 
CAT (Fig. 1C); both these reporter proteins have previ- 
ously been shown to co-localise with endogenous peroxi- 
somal proteins [8]. The PTS1 reporter protein luciferase 
has previously been shown to be imported into peroxi- 
somes in RCDP cells [8]. This reporter protein is also 
targeted to peroxisomes in cell lines CDP1-4. Fig. IB 
shows the expression pattern in CDP1 cells. 
In contrast o the PTS1 reporter protein, expression of 
the PTS2 reporter protein in CDP1 cells gave rise to a 
diffuse pattern of labelling resembling a cytoplasmic local- 
isation (Fig. ID). Labelling patterns imilar to the latter 
were observed with cell lines CDP2-4 (not shown) and 
have also been observed in cells derived from classical 
RCDP patients [8]. The labelling patterns een after ex- 
pression of prethiolase-CAT were similar to those seen 
when endogenous thiolase was visualised using a mono- 
clonal antibody (Fig. 1E,F). 
Thiolase import was assessed further by determining the 
accessibility of endogenous peroxisomal thiolase to pro- 
tease digestion. Precursor thiolase is protected from pro- 
tease digestion in fibroblasts from a neonatal 
adrenoleukodystrophy atient (Fig. 2, upper panel) in which 
import of precursor thiolase has been shown to be intact 
[8]. In all of the CDP patients (of which CDP1 is shown in 
Fig. 2, lower panel), precursor thiolase is degraded by 
proteinase K, presumably because of its failure to be 
imported into peroxisomes. 
The genetic relationship between the four CDP patients 
and a classical RCDP patient was investigated by comple- 
mentation analysis after somatic cell fusion of different 
combinations of fibroblasts. As has been shown by Heikoop 
et al. [13], the appearance of punctate fluorescence using a 
monoclonal anti-thiolase antibody can be taken as a mor- 
phological criterion to indicate complementation. When 
fibroblasts from a Zellweger patient were fused with CDP1 
fibroblasts, a punctate pattern of fluorescence was seen in 
the heterokaryons (Fig. 3A). Similar results were obtained 
after fusion of CDP2-4 with ZS cells (not shown). In 
contrast o the fusions with ZS fibroblasts, no punctate 
fluorescence could be observed when different, pairwise 
combinations of fibroblasts from the CDP patients were 
fused with each other, indicating that cell lines CDP1-4 all 
belong to the same complementation group. Fig. 3B shows 
the labelling pattern 18 h after fusion of cell lines CDP1 
and CDP2. 
In order to investigate whether the CDP patients are 
deficient in the same gene as that deficient in classical 
RCDP patients, cell lines CDP1-4 were each fused with a 
representative c ll line from the large complementation 
group that contains fibroblasts from 9 classical RCDP 
patients [13]. No punctate fluorescence was seen after 
fusions between CDP and classical RCDP cell lines, indi- 
cating that all the cell lines are deficient in the same gene. 
Fig. 3C-F shows the pattern of labelling 18 h after pair- 
wise fusion of cell lines CDPI-4, respectively, with a 
classical RCDP cell line (MCHE 85AD). 
4. Discussion 
The non-rhizomelic chondrodysplasia punctata patients 
analysed in this study have previously been shown to 
possess the biochemical abnormalities characteristic of 
RCDP patients [9-12]. We have compared fibroblasts from 
non-rhizomelic CDP patients to those from a classical 
RCDP patient with respect o their ability to import the 
PTS 1-containing protein luciferase and the PTS2-contain- 
ing protein thiolase. We have also investigated the genetic 
relationship between non-rhizomelic CDP patients and a 
classical RCDP patient using complementation a alysis 
after somatic cell fusion. Fibroblasts from the classical 
RCDP patient have already been shown to belong to the 
same complementation group as 8 other patients with the 
clinical manifestations of RCDP [13]. 
The ability of CDP and RCDP cells to import luciferase 
shows that the PTSI import route is intact in these cells. 
Analysis of (i) the subcellular localisation of a reporter 
protein for the thiolase import route using immunofluo- 
rescence and (ii) the accessibility of endogenous thiolase 
in permeabilised cells to protease degradation has shown 
that precursor thiolase in both RCDP and non-rhizomelic 
CDP fibroblasts failed to be imported into peroxisomes. 
We conclude from the above that the non-rhizomelic CDP 
patients cannot be distinguished from the classical RCDP 
patient either with respect o their ability to import the 
PTSl-containing reporter protein luciferase, or with re- 
spect to their inability to import PTS2-containing peroxiso- 
mal thiolase. 
It was therefore of interest to investigate the genetic 
relationship between the RCDP and the non-rhizomelic 
CDP patients. The failure of punctate thiolase labelling to 
appear after fusion of various combinations of non- 
rhizomelic CDP fibroblasts and RCDP fibroblasts (in con- 
trast to when Zellweger fibroblasts were used as a fusion 
partner) indicates that the non-rhizomelic CDP and RCDP 
fibroblasts all belong to the same complementation group. 
It is striking that defects within one and the same gene can 
give rise to both the rhizomelic and the non-rhizomelic 
forms of CDP. It is possible that the mutations present in 
the non-rhizomelic CDP patients give rise to a protein 
product with higher residual activity than that found in the 
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more severe RCDP patients, as at least one of the CDP 
patients [9] had higher DHAP-AT activity than that found 
in RCDP patients. Support for this possibility is provided 
by Wanders et al., who have described two patients [17,18] 
who showed all the clinical features of RCDP but lacked 
the tetrad of biochemical abnormalities usually found in 
RCDP patients: in both patients, phytanic acid oxidation 
was normal, and thiolase was present in its mature form 
inside peroxisomes. However, both patients howed a defi- 
ciency in plasmalogen biosynthesis: in one patient, the first 
enzyme required for plasmalogen biosynthesis was defi- 
cient (DHAP-AT) [17], while the other patient lacked only 
the second enzyme [18]. These results strongly suggest that 
the pathogenesis of RCDP is directly related to the inabil- 
ity to synthesise plasmalogens [ 17,18]. 
The finding that patients uffering from non-rhizomelic 
and rhizomelic CDP have a deficiency in the same gene 
indicates that the former is simply a milder form of the 
latter. A complementation group which includes patients 
suffering from the peroxisomal disorders Zellweger Syn- 
drome, Infantile Refsum's disease and neonatal 
adrenoleukodystrophy s ows that phenotypic heterogeneity 
within a single complementation group is not unprece- 
dented [15,19-21]. 
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